Stay updated on Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial
Sign up to get notified when there's something new on the Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial page.

Latest updates to the Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check21 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check57 days agoChange DetectedThe webpage has been updated to include a new multicenter phase II study evaluating the combination of denosumab and nivolumab for stage IV non-small-cell lung cancer patients with bone metastases, along with details about the study's inclusion and exclusion criteria. Additionally, the principal investigator's name has been added.SummaryDifference47%
- Check65 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 13, 2025.SummaryDifference0.3%
Stay in the know with updates to Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial page.